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Abstract
Despite the type I insulin-like growth factor receptor (IGF-IR) being highly expressed in more than 80% of human
lung tumors, a transgenic model of IGF-IR overexpression in the lung has not been created. We produced two novel
transgenic mouse models in which IGF-IR is overexpressed in either lung type II alveolar cells (surfactant protein C
[SPC]–IGFIR) or Clara cells (CCSP-IGFIR) in a doxycycline-inducible manner. Overexpression of IGF-IR in either cell
type caused multifocal adenomatous alveolar hyperplasia with papillary and solid adenomas. These tumors ex-
pressed thyroid transcription factor 1 and Kruppel-like factor 5 in most tumor cells. Similar to our previous work with
lung tumors that developed in the mouse mammary tumor virus–IGF-II transgenic mice, the lung tumors that de-
velop in the SPC-IGFIR and CCSP-IGFIR transgenic mice expressed high levels of the cyclic adenosine monophos-
phate response element binding protein that was localized primarily to the nucleus. Although elevated IGF-IR
expression can initiate lung tumor development, tumors can become independent of IGF-IR signaling as IGF-IR
down-regulation in established tumors produced tumor regression in some, but not all, of the tumors. These find-
ings implicate IGF-IR as an important initiator of lung tumorigenesis and suggest that the SPC-IGFIR and CCSP-
IGFIR transgenic mice can be used to further our understanding of human lung cancer and the role IGF-IR plays in
this disease.
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Introduction
Lung cancer is the leading cause of cancer-related deaths for both
men and women in Canada and the United States (Canadian Cancer
Statistics 2007 and National Cancer Institute Statistics 2007). The
devastatingly high mortality rate (approximately 80%) of this disease
is largely attributable to difficulties in early diagnosis and lack of
effective therapies [1–3].
Lung cancer is associated with a number of different epithelial cell
types and broadly classified into small cell lung cancer (SCLC) and non–
small cell lung cancer (NSCLC).Non–small cell lung cancer cells, which
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comprise approximately 75% of the cases of lung cancer, are further
subdivided into squamous cell carcinoma, adenocarcinoma, and large
cell carcinoma [4–7]. These tumors are grouped together based on
their similar response to treatment. Squamous cell carcinomas frequently
arise from segmental bronchi, whereas adenocarcinomas typically arise
in peripheral regions of the lung and may express differentiated fea-
tures of type II alveolar cells or Clara cells [5,8]. Large cell carcinomas
frequently arise in the distal tubules. Small cell carcinomas are usually
found in central endobronchial locations [6]. A number of gene abnor-
malities have been associated withNSCLC includingmutations in p53
[9–14], c-erbB2 (Her2/neu) [15–18], and K-ras [19–23]. In addition to
genetic alterations, there is evidence that inappropriate activation of
the insulin-like growth factor (IGF) signaling may contribute to lung
tumor development.
The IGF family consists of two ligands, insulin-like growth factor
I (IGF-I) and insulin-like growth factor II (IGF-II), the IGF-I receptor
(IGF-IR) and IGF-II receptor (IGF-IIR), and at least six IGF binding
proteins (IGFBP-1 to IGFBP-6) [24–27]. Insulin-like growth factor
signaling has been implicated in promoting growth, development,
and metastasis in many different types of cancer (reviewed in [28–32]).
In the normal lung, IGF-I and IGF-II are expressed by a number of
lung cell types in including epithelial cells, fibroblasts and macro-
phages [33]. Insulin-like growth factors are expressed in the lung
during alveolarization and are required for increasing proliferation of
mesenchymal and epithelial cells during lung morphogenesis [34].
With respect to lung cancer, high plasma IGF-I levels and low
plasma IGFBP-3 levels have been associated with increased lung cancer
risk [35]. In addition, IGF-IR is expressed at high levels in 95% of
human SCLCs and 80% of NSCLCs [36–38], whereas adenocarci-
noma patients with a higher number of IGF-II–positive cells were
reported to have a worse prognosis than patients with lung tumors con-
taining low IGF-II staining [39]. Studies on human lung tumor cell
lines have also implicated the IGF family in lung tumorigenesis because
administration of IGF-I or IGF-II promotes proliferation of SCLC
and NSCLC cell lines [40–42], whereas targeting the IGF-IR inhibits
lung tumor cell proliferation and sensitizes lung tumor cells to chemo-
therapy and radiotherapy [42–48].
A more complete understanding of the function of the IGF family
in lung tumorigenesis has been hampered by the paucity of appropriate
animal models. Our laboratory has demonstrated that transgenic
Figure 1. Immunohistochemistry for IGF-IR in SPC-IGFIR (A), CCSP-IGFIR (B), or wild-type (C) mouse treated with doxycycline for
2 months. Immunofluorescence for IGF-IR (D) and CCSP (E) in a CCSP-IGFIR mouse and IGF-IR (G) and pro-SPC (H) in an SPC-IGFIR
mouse treated with doxycycline. Merged images of IGF-IR/CCSP (F) and IGF-IR/SPC (I). Scale bars, 100 μm.
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overexpression of IGF-II in the lung was sufficient to induce lung tu-
mors [49]. These tumors were associated with enhanced activation of
Erk1/2, p38 mitogen-activated protein kinase, and the transcription
factor cAMP response element binding protein (CREB) [49]. The use-
fulness of the IGF-II transgenic model is limited by indirect transgene
targeting (IGF-II transgene expression is regulated by the mouse mam-
mary tumor virus [MMTV] promoter which directs transgene expres-
sion primarily to the mammary epithelium but can also drive
expression in other tissues such as the lung), prolonged tumor latency
(∼18 months), and incomplete penetrance of the tumor phenotype.
To overcome the aforementioned limitations of the IGF-II trans-
genic model and to provide a model to directly assess the importance
of IGF signaling in lung tumorigenesis, our laboratory created trans-
genic mice that expressed high levels of the human IGF-IR comple-
mentary DNA in type II alveolar cells or Clara cells of the lung.
Characterization of these lung-specific IGF-IR transgenic mice in the
current study revealed that elevated IGF-IR expression in either type
II alveolar or Clara cells induced epithelial hyperplasia and focal tumors.
These tumors also expressed high levels of CREB, thyroid transcrip-
tion factor 1 (TTF-1), and Kruppel-like factor 5 (KLF5). Interestingly,
tumors initiated by IGF-IR can become independent of IGF-IR signal-
ing. In these IGF-IR–independent tumors, CREB protein expression
remained high suggesting that this protein may be critical for continued
tumor growth.
Materials and Methods
Mice
Surfactant protein C (SPC)–reverse tetracycline transactivator (rtTA)
and Clara cell secretory protein (CCSP)–rtTA mice were generated pre-
viously as described [50]. Tetracycline response element (TRE)–IGFIR
transgenic mice were generated previously in our laboratory [51]. The
SPC-rtTA and CCSP-rtTA transgenic mice were then mated with
TRE-IGFIR transgenic mice producing the desired double transgenic
mice designated as SPC-IGFIR and CCSP-IGFIR. Doxycycline-treated
mice were fed chow supplemented with 2 g of doxycycline per kilogram
of rodent chow (Bio-Serv, Frenchtown, NJ) beginning at 21 days of
age. Mice were maintained and cared for following Canadian Council
for Animal Care guidelines.
Figure 2. (A, B) Macroscopic images of lung tumors from a 9-month-old SPC-IGFIR transgenic mouse. Hematoxylin and eosin–stained lung
sections from a CCSP-IGFIR transgenic mouse (C, E) and an SPC-IGFIR transgenicmouse (D, F). Scale bars, 800 μm (C, D) and 100 μm (E, F).
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Figure 3. Immunohistochemistry for IGF-IR (A, B), pro-SPC (C, D), CCSP (E, F), TTF-1 (G, H), and KLF5 (I, J) in a lung tumor from a doxycycline
treated CCSP-IGFIR transgenic mouse (A, C, E, G, I) or a doxycycline-treated SPC-IGFIR transgenic mouse (B, D, F, H, J). Scale bars, 100 μm.
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Western Blot Analysis
Western blot analysis was performed as described in Jones et al. [51]
and Linnerth et al. [52]. All primary antibodies, anti–IGF-IR (R&D
Systems, Inc., Minneapolis, MN), anti–phospho-IGFIR, anti–phospho-
Akt, anti-Akt, anti–phospho-CREB, anti-CREB (Cell Signaling Tech-
nology, Beverly, MA), and antitubulin (Santa Cruz Technologies, Santa
Cruz, CA), were used at a 1:1,000 dilution. Secondary antibodies (Cell
Signaling Technology) were used at a 1:2,000 dilution. Images were cap-
tured on a FluorChem 9900 gel documentation system (Alpha Innotech,
San Leandro, CA).
Immunohistochemistry and Immunofluorescence
Two different procedures were used for immunohistochemistry.
Immunohistochemistry for TTF-1, KLF5, pro-SPC, and CCSP were
performed in Dr. Jeffery Whitsett’s laboratory using previously de-
scribed methods [53–56]. Immunohistochemistry for IGF-IR, pAkt,
and CREBwere performed in our laboratory using previously described
methods [52]. The primary antibodies were used at a 1:100 dilution,
and the pAkt and CREB antibodies were obtained from Cell Signaling
Technology, whereas the IGF-IR antibody was obtained from R&D
Systems, Inc. Immunofluorescence was performed in our laboratory
using previously described methods [52]. The pro-SPC and CCSP anti-
bodies (Abcam, Cambridge, MA) were used at a 1:500 dilution for the
immunofluorescence experiments. All experiments included primary
and secondary antibody omission controls.
Tissue Array
A lung cancer tissue array (US Biomax, Inc., Rockville,MD) contain-
ing lung tumors from 192 patients and 8 cases of normal tissue was used
for this study. The immunohistochemical procedure was previously de-
scribed in Linnerth et al. [52]. The anti-CREB antibody (Cell Signaling
Technology) was used at a dilution of 1:50 in 5% BSA. CREB stain-
ing intensity was measured using ImageScope analysis software (Aperio,
Vista, CA) and categorized as less than 10% of the tumor cells staining
positive for CREB, 11% to 20%, 21% to 30%, or more than 30%
staining positive for CREB. CREB nuclear localization was scored by
the investigator and was grouped into the classifications listed above.
Results
Generation and Characterization of Doxycycline-Inducible
IGF-IR Mice
To prevent complications arising from altered gene expression dur-
ing lung morphogenesis, we have used a doxycycline inducible system
to express the IGF-IR transgene. This system uses two activator con-
structs (SPC-rtTA or CCSP-rtTA) and one target construct (TRE-
IGFIR). The 3.7-kb human SPC gene promoter drives expression of
the rtTA primarily in type II alveolar cells, and the 2.3-kb rat CCSP gene
promoter drives expression of the rtTA primarily in Clara cells [50].
TRE-IGFIR transgenic mice have been described previously [51]. In
the absence of doxycycline, the rtTA protein is unable to bind to the
TRE, and thus, only transgenic mice bearing both an activator construct
(SPC-rtTA or CCSP-rtTA) and the target construct (TRE-IGFIR) in
the presence of doxycycline express the IGF-IR transgene.
To determine the effect of IGF-IR expression in type II alveolar cells
or Clara cells, SPC-IGFIR and CCSP-IGFIR transgenic mice were
administered doxycycline beginning at 21 days of age. Lungs from
SPC-IGFIR and CCSP-IGFIR were then collected at various intervals
after the initiation of doxycycline treatment. At the earliest time point
examined (1 month after the initiation of doxycycline treatment), cells
expressing IGF-IR were observed in all doxycycline-treated SPC-IGFIR
and CCSP-IGFIR transgenic mice. In SPC-IGFIR mice, alveolar
epithelial cells were found to express high levels of IGF-IR (Figure 1A).
In CCSP-IGFIR mice, cells expressing high levels of IGF-IR were
found in the bronchiolar epithelium and in the alveolar epithelium
(Figure 1B). Only low levels of IGF-IR expression were observed in
wild-type or single transgenic mice treated with doxycycline (Fig-
ure 1C). Double transgenic mice not exposed to doxycycline displayed
IGF-IR levels similar to lungs from wild-type mice (data not shown).
To further assess the cell type expressing high levels of IGF-IR, dual-
labeling immunofluorescence was used. In CCSP-IGFIR transgenic
mice, IGF-IR protein was found to be expressed in cells lining the
bronchi that also stained positive for CCSP (Figure 1, D–F ) and in
alveolar epithelial cells (data not shown). In SPC-IGFIR transgenic
mice, IGF-IR protein was expressed in pro-SPC–positive, type II alve-
olar cells (Figure 1, G–I ).
IGF-IR Transgene Expression Induces Alveolar Epithelial
Hyperplasia and Adenomas
Macroscopic tumors were visible on the lung surface in both SPC-
IGFIR and CCSP-IGFIR mice as early as 90 days after the initiation
of IGF-IR transgene expression (data not shown). In SPC-IGFIR
and CCSP-IGFIR mice treated with doxycycline for up to 9 months,
macroscopically visible lung tumors (2-30 tumors) were detected in
most mice. Macroscopic lesions presented as white, solid masses, vary-
ing in size and location on the lung (Figure 2, A and B). Histologi-
cally, lungs from all SPC-IGFIR and CCSP-IGFIR mice treated with
doxycycline for 9 months displayed multifocal adenomatous alveolar
Figure 4. Western blot of phosphorylated IGF-IR (pIGF-IR), IGF-IR,
phosphorylated Akt (pAkt), Akt, phosphorylated CREB (pCREB),
CREB, and phosphorylated ATF-1 (pATF-1) in wild-type (WT), SPC-
IGFIR, or CCSP-IGFIR transgenic mice administered doxycycline for
8 months. Tubulin served as a loading control.
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hyperplasia (AAH) with papillary and solid adenomas. Bronchiolar
hyperplasia was not observed in either genotype (Figure 2, C–F).
Immunohistochemistry for IGF-IR, pro-SPC, and CCSP revealed
that the hyperplasia/tumors expressed high levels of IGF-IR (Figure 3,
A and B), variable levels of pro-SPC (Figure 3,C andD), and no detect-
able CCSP protein (Figure 3, E and F ). Thyroid transcription factor 1
(Figure 4, G and H ) and KLF5 (Figure 3, I and J ) were expressed in
almost all of the tumor cells.
IGF-IR–Induced Lung Tumors Contain High
Levels of Nuclear CREB
Although there was some variability, most of the lung tissue collected
from SPC-IGFIR or CCSP-IGFIR transgenic mice treated with doxy-
cycline for 8months contained higher levels of IGF-IR, phospho-IGFIR,
phospho-Akt, and phospho-CREB compared with doxycycline-treated
wild-type mice (Figure 4). The phospho-CREB antibody also detects
phospho–ATF-1 (a CREB binding partner), and this phosphorylated
Figure 5. Immunohistochemistry for IGF-IR (A, D), phosphorylated Akt (B, E), and phosphorylated CREB (C, F) in lung tumors fromSPC-IGFIR
(A–C) and CCSP-IGFIR (D–F) mice treated with doxycycline for at least 8 months. Immunofluorescence for IGF-IR (G, J), phosphorylated Akt
(H), and phosphorylated CREB (K) in a lung tumor from an SPC-IGFIR transgenic mouse treated with doxycycline for at least 8 months.
Merged images of IGF-IR/phosphorylated Akt (I) and IGF-IR/phosphorylated CREB (L). Scale bars, 100 μm.
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protein was also elevated in the transgenic lung tissue compared with
wild-type controls.
Immunohistochemistry and immunofluorescence revealed that
IGF-IR (Figure 5, A and D), phospho-Akt (Figure 5, B and E ), and
phospho-CREBwere highly expressed in the lung tumor cells compared
with the normal surrounding cells (Figure 5, C and F ). Phospho-p38
mitogen-activated protein kinase, but not pErk1/2, was also highly ex-
pressed in the lung tumor cells (data not shown). Tumor cells expressing
high levels of phospho-Akt (Figure 5H) or phospho-CREB (Figure 5K )
coexpressed high levels of IGF-IR (Figure 5, G , I , J , and L).
As high levels of CREB were observed in lung tumors arising in
MMTV-IGF-II [49], SPC-IGFIR, and CCSP-IGFIR transgenic mice,
CREB expression was examined in human lung tissue. Most of the
human lung adenocarcinomas, squamous cell carcinomas, and small
cell carcinomas expressed moderate or high levels of CREB (Figure 6A)
with most of this CREB being localized to the nucleus (Figure 6B).
Incomplete Tumor Regression after IGF-IR Down-regulation
To determine whether IGF-IR–induced tumors remained dependent
on IGF-IR signaling, doxycycline was withdrawn from SPC-IGFIR
and CCSP-IGFIR transgenic mice after an 8-month treatment period.
Lung tissue was then collected 96 hours, 2 weeks or 1 month after the
removal of doxycycline. Of the threemice examined (twoCCSP-IGFIR
and one SPC-IGFIR) after a 96-hour doxycycline withdrawal, the lungs
of all of the mice displayed either IGF-IR–positive cells or IGF-IR–
positive tumors (data not shown). Of the three mice examined after a
2-week doxycycline withdrawal period, one CCSP-IGFIR transgenic
mouse lung contained IGF-IR–positive cells and several IGF-IR-positive
tumors, one SPC-IGFIR transgenic mouse lung contained IGF-IR-
positive cells and at least one tumor with both IGF-IR–positive and
–negative cells, whereas one CCSP-IGFIR transgenic mouse lung con-
tained IGF-IR–positive tumors and a few areas that resembled com-
pletely regressed tumor lesions (data not shown). Eight mice (six
SPC-IGFIR and two CCSP-IGFIR) were examined after a 1-month
doxycycline withdrawal period. Lung tissue from one of the CCSP-
IGFIR transgenic mice did not contain any IGF-IR–positive cells or
apparent tumors but did contain several regions that resembled re-
gressed tumor lesions (Figure 7A). These areas of tumor regression
are similar to the mammary tumors that regressed after doxycycline
withdrawal in MMTV-IGFIR transgenic mice (unpublished observa-
tions). Three of the mice (all SPC-IGFIR) contained only tumors that
were primarily negative for IGF-IR staining (Figure 7C ), whereas two
of the mice (both SPC-IGFIR) contained either IGF-IR–positive cells
or IGF-IR–positive tumors (Figure 7B). The remaining two mice (one
SPC-IGFIR and one CCSP-IGFIR) contained both IGF-IR–positive
and –negative tumors. Some of the tumors in the lungs of these
mice also demonstrated a mixture of IGF-IR–positive and IGF-IR–
negative cells (Figure 7D). Immunohistochemistry revealed that
CREB (Figure 8, A and B) and KLF5 (data not shown) were expressed
at high levels in tumors where IGF-IR levels were mixed (Figure 8C ) or
absent (Figure 8D).
Discussion
The IGF-IR has been associated with human SCLC and NSCLC
in that the IGF-IR is highly expressed in approximately 95% of SCLC
and 80% of NSCLC cases [36–38]. In addition, studies on human
lung cancer cell lines demonstrated that IGF signaling promotes lung
tumor proliferation and inhibits apoptosis, whereas down-regulation
of IGF-IR inhibits lung tumor cell proliferation, promotes apoptosis,
and sensitizes lung cancer cells to chemotherapy and radiotherapy
[42–48]. Although these studies demonstrate that IGF signaling is
an important regulator of lung tumorigenesis, they do not address
whether IGF signaling mediates transformation of normal lung cells
and is thus involved in tumor initiation or whether IGF-IR primarily
mediates lung tumor progression. Our characterization of SPC-IGFIR
and CCSP-IGFIR transgenic mice demonstrated that elevated levels
of IGF-IR and hyperactive IGF-IR signaling are sufficient to promote
lung tumor initiation. This finding supports our previous transgenic
model where elevated levels of IGF-II induced pulmonary tumorigen-
esis [49].
Interestingly, IGF-IR overexpression in Clara cells produced solid
adenomas that were largely negative for the Clara cell marker CCSP.
Loss of CCSP expression has been observed in at least two other trans-
genic models of lung tumorigenesis, the CC10TAg transgenic mice and
the CCSP-rtTA-FGF10 transgenic mice [57,58]. There are at least
three possible explanations for the loss of Clara cell protein markers
in lung tumors arising from CCSP-targeted transgenes. First, it is pos-
sible that upon transformation, Clara cells undergo changes in gene
expression leading to very low levels of the Clara cell marker [59].
An alternative explanation is that the CCSP promoter is expressed in
both Clara cells and type II alveolar cells, and only type II alveolar cells
are transformed and thus give rise to tumors [57]. As we observed ele-
vated IGF-IR levels in Clara cells as well as cells in the lung periphery
in the CCSP-IGFIR transgenic mice, and there is no apparent bron-
chiolar hyperplasia, it is possible that type II alveolar cells are the cells
Figure 6. Quantification of CREB protein levels (A) and nuclear
localization (B) in normal lung or lung tumors cores.
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of origin for the tumors in both the SPC-IGFIR and CCSP-IGFIR
transgenic mice. However, the solid adenomas in the CCSP-IGFIR
transgenic mice are largely negative for SPC staining, whereas the
adenomas in the SPC-IGFIR transgenic mice are primarily SPC-
positive. A final explanation involves putative bronchioalveolar stem
cells (BASCs). Bronchioalveolar stem cells are cells located between
the conducting and respiratory epithelium in a region termed the
bronchioalveolar duct junction [60]. Bronchioalveolar stem cells have
been identified as cells expressing both SPC and CCSP proteins that
increase in number in response to lung injury. Therefore, it is possible
that the IGF-IR transgene may be expressed in the proposed BASC
“stem” cells as well as in Clara cells and type II alveolar cells. Prolifer-
ation of BASC cells expressing high levels of IGF-IR may differentiate
toward lung cells expressing SPC or neither SPC nor CCSP.
Most of the tumor cells in both SPC-IGFIR and CCSP-IGFIR trans-
genic mice expressed high levels of CREB regardless of their expression
of SPC or CCSP proteins. High levels of CREB were also a consistent
finding in ourMMTV-IGF-II induced lung tumors [49]. TheCREB in
all three transgenic models primarily localized to the nuclei of the tumor
cells suggesting that the CREB was phosphorylated. Moreover, our
study found a high level of CREBand nuclear localizedCREB in human
lung cancer samples suggesting that CREB is an important mediator of
lung tumorigenesis.
cAMP response element binding protein was first implicated in lung
tumorigenesis by Wardlaw et al. [61] when this group demonstrated
that lung tumors induced by NNK [4-(methylnitrosamino)-1-(3-
pyridal)-1-butanone] had mutations in the CREB/ATF binding site
which resulted in the inhibition of COX-2 promoter activity. A number
of additional studies have also demonstrated that CREB is an important
mediator of lung tumorigenesis in human cell lines and human lung
tumor samples. Aggarwal et al. [62] reported that targeting CREB using
a R0-31-8220 inhibitor resulted in suppression of cell growth and tu-
morigenicity inNSCLC cells.We demonstrated that dominant-negative
CREB vectors inhibited soft agar growth ofNSCLC cell lines [52].More
recently, a study has shown that CREB is elevated in human NSCLC
and is associated with a poor prognosis [63]. Our studies on CREB in
human lung tumor tissue agree with this study [63] in that CREB stain-
ing was higher in the lung tumors compared with normal tissue. Thus,
CREB is emerging as an important regulator of human lung tumorigen-
esis and may serve as a therapeutic target or biomarker for lung cancer;
Figure 7. Immunohistochemistry for IGF-IR in the lungs from mice treated with doxycycline for 8 months followed by a 1 month with-
drawal of doxycycline. (A) Mouse with apparent regressed tumor lesions, (B) a tumor containing primarily IGF-IR–positive cells, (C) a
tumor containing exclusively IGF-IR–negative cells, and (D) a number containing both IGF-IR–positive and IGF-IR–negative cells. The
inset is a higher magnification of the stained slide. Scale bars, 50 μm; insets, 100 μm.
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two areas being actively investigated in our SPC-IGFIR and CCSP-
IGFIR transgenic mice.
In addition to CREB, TTF-1 and KLF5 were highly expressed in a
majority of tumor cells in the SPC-IGFIR and CCSP-IGFIR mice.
Thyroid transcription factor 1, a transcription factor critical for airway
formation and epithelial differentiation, is often expressed at high
levels in NSCLC [64–70]. In contrast, KLF5 has not previously been
described in lung tumors. Kruppel-like factor 5 is a member of the zinc
finger transcription factor family Sp1 and was originally identified in the
intestinal epithelium [53]. Since its discovery, KLF5 has also been found
in the tongue, epidermis, trachea, and bronchial epithelial cells. The im-
portance of KLF5 in normal lung development was demonstrated in
mice where the KLF5 gene was conditionally deleted in lung epithelial
cells [53]. Loss of lung epithelial KLF5 disrupted lung development
during the saccular stage, and mice died of respiratory distress immedi-
ately after birth [53]. The saccules of the KLF5 null mice were hypercel-
lular and were not as dilated as the saccules of lungs from wild-type
mice. Interestingly, a similar phenotype was observed in the lungs of
mice lacking IGF-II [71]. Although KLF5 has not been associated with
lung tumorigenesis, it has been observed in colon, gastric, and intestinal
tumors [72–74]. The function of KLF5 in IGF-IR–induced lung
tumorigenesis and whether IGF-IR signaling directly regulates KLF5
expression is currently under investigation in our laboratory.
Lung tumor development in transgenic mice that express high levels
of IGF-IR demonstrates the importance of IGF-IR in tumor initiation.
However, the IGF-IR may only represent a viable therapeutic target if
the lung tumors remain dependent on IGF-IR expression for continued
growth and survival. Down-regulation of IGF-IR transgene expression
(through doxycycline withdrawal) in mice treated with doxycycline
for 8 months revealed that some tumor cells remained despite little
or no IGF-IR expression. Because our IGF-IR antibody detects endog-
enous and transgenic IGF-IR, these tumors remained in the absence
of elevated IGF-IR expression. Intriguingly, CREB and KLF5 are still
expressed in these IGF-IR–negative tumors suggesting that they may
be important regulators of lung tumorigenesis. These findings suggest
that some tumors that are initiated by IGF-IR overexpression acquire
additional genetic alterations that render the tumor cells independent
of IGF-IR signaling for growth and survival. In the case of the lung
tumors, this IGF-IR independence may be associated with CREB
and/or KLF5 activation through an alternative signaling pathway. In
Figure 8. Immunohistochemistry for CREB (A, B) in lung tumors after doxycycline withdrawal that display mixed IGF-IR expression (C) or
no IGF-IR expression (D).
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ourmammary tumormodel, tumors initiated by IGF-IR overexpression
also display IGF-IR–independent tumor growth [75] indicating that
this escape from IGF-IR dependence is not restricted to lung tumors.
Development of IGF-IR independence has important clinical ramifica-
tions because it suggests that some lung tumors could either acquire or
be intrinsically resistant to IGF-IR targeting agents.
In summary, using IGF-IR transgenic mice, we have shown that
IGF-IR overexpression in type II alveolar cells or Clara cells is sufficient
to initiate lung tumor development; however, continued growth of
these lung tumors is not explicitly dependent on continued IGF-IR ex-
pression. Two proteins that may mediate IGF-IR induced lung tumori-
genesis and possibly tumor escape from IGF-IR dependence are CREB
and KLF5. Therefore, CREB and KLF5 may represent more viable
therapeutic targets for the treatment of lung cancer than IGF-IR.
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